Built on a solid knowledge platform
Xinnate is built on more than 15 years of world class research by professor Artur Schmidtchen and his team at Lund University. Xinnate operates in close cooperation with Professor Schmidtchen with the aim to further develop and commercialize the proprietary novel peptide platform, TCP-25 in the areas of wounds, inflammatory skin diseases, surgery and biomaterials.
The mode of action of TCP-25 is well investigated and understood, and there is a proven therapeutic effect of TCP-25 on infection and healing.
Read more about: